Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 3/20 | 0.43 |
| ▸ | ME2 | P23368 | 1/20 | 0.41 |
| ▸ | ME1 | P48163 | 1/20 | 0.41 |
| ▸ | ME3 | Q16798 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808620 | 0.92 | DRD4 (0.47) | DRD4DRD3HTR1AHTR2ASLC6A4 | |
| Hydrochloric Acid SCHEMBL6812180 | 0.91 | GPR119 (0.50) | DRD4DRD3HTR1AHTR2ASLC6A4 | |
| SCHEMBL5238753 | 0.83 | DRD4 (0.55) | DRD4DRD3HTR1AHTR2ASLC6A4 | |
| SCHEMBL31589397 | 0.78 | HTR1A (0.52) | DRD4DRD3HTR1AHTR2ASLC6A4 | |
| SCHEMBL12911528 | 0.77 | GPR119 (0.58) | DRD4DRD3HTR1AHTR2ASLC6A4 | |
| SCHEMBL1742814 | 0.77 | HRH3 (0.52) | DRD4DRD3HTR1AHTR2ASLC6A4 | |
| Hydrochloric Acid SCHEMBL942193 | 0.76 | GPR119 (0.56) | DRD4DRD3HTR1AHTR2ASLC6A4 | |
| Hydrochloric Acid SCHEMBL6786442 | 0.76 | GPR119 (0.56) | DRD4DRD3HTR1AHTR2ASLC6A4 | |
| SCHEMBL941651 | 0.75 | AKR1C3 (0.57) | CNR2RETKDM4EMEN1NPC1 | |
| SCHEMBL18621601 | 0.75 | GRIN2D (0.51) | DRD4DRD3HTR1AHTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| CN-101602731-A | Inhibitors of metalloproteinase | ASTRAZENECA AB (SE) | 2009-12-16 | — | — | CN | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| CN-100526307-C | Metalloprotease inhibitors | ASTRAZENECA AB (SE) | 2009-08-12 | — | — | CN | disclosed |
| US-20080306065-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-7427631-B2 | especially as inhibitors of MMP12 | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1370556-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1676846-A2 | Hydantoin derivatives as MMP inhibitors | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| CN-1509275-A | Metalloproteinase inhibitors | — | 2004-06-30 | — | — | CN | disclosed |
| CN-1509286-A | Metalloprotease inhibitors | — | 2004-06-30 | — | — | CN | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370556-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | DRD4 4741/4885DRD3 4806/4885HTR1A 3455/4885 |
| US-20080306065-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | DRD4 4741/4885DRD3 4806/4885HTR1A 3455/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | DRD4 4741/4885DRD3 4806/4885HTR1A 3455/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | DRD4 3475/4885DRD3 2798/4885HTR1A 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.